Ferroptosis, a form of regulatory non-apoptotic cell death driven by iron-dependent lipid peroxidation, accounts for more than 80% of the total types of neuronal death in the acute phase of ...

Mitochondria were centrifuged at 2,000 g for 20 min at 4°C, then 50 μL/well assay solution was supplemented with succinate, rotenone, ADP, and MitoSOX Red (final concentrations 10 mmol/L, 2 ...

In this segment, the experts discuss the selection criteria among four available JAK inhibitors—ruxolitinib, fedratinib, pacritinib, and momelotinib—for myelofibrosis treatment. Dr. Rampal notes that ...

We demonstrate that substitutionally inert octahedral metal complexes, such as the iridium (III) carbene complex (1a), provide a useful source of potent inhibitors for unexplored oncogenic protein ...

In this work, we carried out neurochemical and behavioral analysis of zebrafish (Danio rerio) treated with rotenone, an agent used to chemically induce a syndrome resembling Parkinson’s disease (PD).

Afimetoran (BMS 986256) is a potent, selective, and orally bioavailable inhibitor of TLR7/8 currently in clinical development for immune mediated diseases. Previously, we observed that afimetoran ...

Panelists discuss potential changes to clinical pathways for Bruton tyrosine kinase (BTK) inhibitor therapies as a result of the Inflation Reduction Act (IRA), focusing on how shifting costs and ...

Next, experts said, discussions will focus on other decisions, such as when and whether to prescribe the SGLT2 inhibitors with GLP-1 receptor agonists for the best outcomes. The Path From Glucose ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...

SUPPLEMENTARY INFORMATION: Background On January 2, 2025, Commerce published in the Federal Register the preliminary results of the administrative review of the antidumping duty order [1] on corrosion ...

197. Arangalage D, Degrauwe N, Michielin O, Monney P, Özdemir BC. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.